InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Mann Brenda, VP of Research & Development. Officer active across 1 company, notably Eyegate Pharmaceuticals INC. Aggregated, 14 filings have been published. Activity tracked since 4 May 2021. The latest transaction was filed on 2 November 2021 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Declarations14 total
62 shares@ US$1.987.3% of flowCommon StockSEC:0001104659-21-133652
62 shares@ US$1.983.0% of flowCommon StockSEC:0001104659-21-133652:0
62 shares@ US$2.013.0% of flowCommon StockSEC:0001104659-21-123266:0
62 shares@ US$2.017.4% of flowCommon StockSEC:0001104659-21-123266
61 shares@ US$1.812.6% of flowCommon StockSEC:0001104659-21-112937:0
61 shares@ US$1.812.6% of flowCommon StockSEC:0001104659-21-112937
63 shares@ US$2.403.6% of flowCommon StockSEC:0001104659-21-100197:0
63 shares@ US$2.403.6% of flowCommon StockSEC:0001104659-21-100197
154 shares@ US$3.7013.5% of flowCommon StockSEC:0001104659-21-089443
154 shares@ US$3.7013.5% of flowCommon StockSEC:0001104659-21-089443:0
155 shares@ US$4.1915.1% of flowCommon StockSEC:0001104659-21-077763:0
155 shares@ US$4.1915.1% of flowCommon StockSEC:0001104659-21-077763
191 sharesCommon StockSEC:0001104659-21-061946
191 shares@ US$4.1318.5% of flowCommon StockSEC:0001104659-21-061946:0
14 of 14 declarations
About Mann Brenda
Brenda Mann is the Vice President of Research & Development at Eyegate Pharmaceuticals Inc. She is responsible for leading research and development initiatives aimed at innovating and improving the company's products.
